molim Inc.

🌟 Enhancing Medical Imaging: Nuclear Medicine vs. Fluorescence Imaging 🌟 At molim Inc., we’re committed to advancing healthcare through innovative imaging technologies. Today, we’re exploring a detailed comparison between two key imaging modalities: Nuclear Medicine Molecular Imaging (SPECT/PET) 🔬 and Fluorescence Imaging (IVIS) 💡. 💡 Fluorescence Imaging: Strengths and Limitations ⚡ Strengths: Effective for visualizing shallow tissues like the liver or tumors and useful for localized, small-scale research. ⚠️ Limitations: - Limited Tissue Penetration: Fluorescence imaging relies on light emitted by fluorescent substances. However, biological tissues scatter and absorb light, making it difficult to observe deep and complex organs like the brain accurately. - Dense Structure of Cerebral Blood Vessels: The brain's dense network of blood vessels makes it hard for fluorescence imaging to distinguish whether signals come from the bloodstream or actual brain tissue. - Presence of the Blood-Brain Barrier (BBB): The BBB is a protective cellular structure that blocks many substances from entering brain tissue. Fluorescence imaging lacks the resolution to determine whether a drug remains in the bloodstream or has passed through the BBB and reached brain tissue. - Quantification Challenges: As a qualitative tool, fluorescence imaging can detect the presence of fluorescent substances but cannot measure their concentration or confirm that they have reached the intended target site. 🔎 How Nuclear Medicine Imaging Solves These Challenges ✔️ Quantitative Measurements: Nuclear medicine molecular imaging (SPECT/PET) provides real-time, quantitative measurements of radioactive tracer absorption, confirming whether drugs have crossed the BBB or reached the target organ. ✔️ Deep Tissue Visualization: Gamma rays emitted by radioactive tracers can penetrate deep tissues, such as the brain, producing clear and detailed images even in complex organs. ✔️ Precise Targeting: Labeling drugs or molecules with radioisotopes enables high specificity, allowing nuclear imaging to distinguish between bloodstream activity and actual target organ uptake. 🚀 Case Study: Addressing Real-World Challenges The limitations of fluorescence imaging, as highlighted above, are well-documented. For example, in deep and complex tissues like the brain, fluorescence imaging struggles to confirm whether drugs have crossed the BBB or merely circulated in the bloodstream. On the other hand, nuclear medicine molecular imaging provides quantitative, organ-specific insights, making it the superior choice for overcoming these challenges. At molim Inc., we leverage advanced nuclear medicine molecular imaging to provide actionable data and accelerate drug development. From tracking drug distribution to confirming its precise localization, our technologies redefine possibilities in medical imaging.

🌟 Join Us at the 10th CLEVERcns Academic Seminar! 🌟 We are thrilled to announce that Hyunsoo Park, CEO of molim Inc., will be the keynote speaker at this prestigious event! 🧬✨ 📅 Date and Time: December 18, 2024 (Wednesday) | 17:00 ~ 18:00 📍 Location: Cyber Lab, 6th floor, Biomedical Research Institute, Seoul National University Hospital 🎙️ Topic: Visualizing and Quantitatively Analyzing the Distribution and Action of New Drug Candidates at the Tissue, Cell, and Molecular Level How to Attend: 💻 Online via Zoom or On-site participation available. 🔗 Register here: https://lnkd.in/gjNUhpg3 (Note: The link may not open on the hospital network. Please use an alternate network or mobile device.) This is a fantastic opportunity to explore cutting-edge innovations in nuclear medicine molecular imaging and gain insights from Dr. Park's expertise. Don't miss out! 🚀 For further details, check out the seminar poster. 🖼️ #CLEVERcns #MolecularImaging #NuclearMedicine #DrugDevelopment #molimInc #Innovation #AcademicSeminar #Collaboration

🚀 Exciting News from molim Inc.! 🎤 Today, our CEO, Hyun Soo Park delivered an insightful presentation at the 2024 Fall Symposium of the Korean Society of Molecular Imaging, hosted at KAIST. 📚 The topic? "Immuno-PET in antibody drug development: From target validation to clinical translation" 🧬🔍 💡 Dr. Park shared cutting-edge advancements in nuclear medicine molecular imaging and how Immuno-PET is revolutionizing antibody drug development, accelerating the journey from research to real-world applications. 💪 At molim Inc., we’re proud to lead innovation and empower bio-researchers with actionable insights. 🌟 Let’s continue pushing boundaries together! #molimInc #MolecularImaging #ImmunoPET #DrugDevelopment #Innovation #KAIST

As highlighted by our CEO, the recent Bio-Europe 2024 event provided invaluable insights and reaffirmed our commitment to transforming healthcare through advanced molecular imaging technology. At molim, we are driven by our mission to support the success of bio-researchers worldwide with cutting-edge science and technology. Together, let’s continue to innovate for a healthier future! 🌍💡 #molim

A snapshot from the field at 2 AM. 🌌 You can truly feel the passion and dedication of our researchers at molim! 🔬💪 At molim, we’re committed to supporting our clients’ success in bio-research through advanced science and technology. This is our mission, and we’re here to make it happen, every step of the way. 🌱🚀 #molim

🌟 Reflecting on BIO-Europe 2024 – A Unique and Positive Experience!🌟 molim Inc. had an incredible opportunity to be part of BIO-Europe 2024, held in Stockholm, Sweden, from November 4th to 6th. With over 5,500 attendees from 2,800+ companies representing 60 countries, the event was an inspiring showcase of innovation and global collaboration. Representing molim Inc., our Founder and CEO Dr. Hyun Soo Park and Project Manager Yujung Jang were thrilled to introduce our cutting-edge nuclear medicine molecular imaging services at Booth 8. The on-site response was exceptional—characterized as unique, surprising, and innovative. This reaction underscored that while nuclear medicine molecular imaging is still unfamiliar to many, it was seen as a positive novelty in the European market. 🌍✨ This fresh perspective affirmed the strong marketability and potential of our services, which accelerate new drug development through real-time, non-invasive imaging and quantification. We are proud to bring this groundbreaking technology to the forefront, empowering bio-researchers and contributing to faster, more confident decision-making in drug development. Thank you to everyone we connected with for your warm reception and interest in our innovative approach! #BIOEurope2024 #NuclearMedicine #MolecularImaging #Innovation #DrugDevelopment #molimInc #GlobalImpact #BiotechLeadership

📢 Don't Miss the 9th CLEVERcns Seminar at Seoul National University Hospital! We’re thrilled to invite you to this unique seminar by Daeseung Lee, MD, MBA, CEO of Portrai Inc., where he will share his expertise on drug effectiveness evaluation using spatial transcriptome technology. Dr. Lee brings a wealth of experience from diverse roles across healthcare, blockchain, and biotech industries. Daeseung Lee's Background: Dr. Lee has been at the helm of Portrai Inc. since 2021, guiding the company’s advancements in biopharmaceuticals. He has proven expertise in integrating medical science with cutting-edge technology. Event Details: 📅 Date & Time: Wednesday, November 27, 2024 | 17:00–18:00 📍 Location: Cyber Lab, Biomedical Research Institute, Seoul National University Hospital 💻 Online Access: Available via Zoom 🧬 Topic: Drug Effectiveness Evaluation Using Spatial Transcriptome How to Attend: Register through the online application form or by scanning the QR code on the poster. (Note: Link may not work on the hospital network; use a mobile device or alternate network.) A light snack will be available for those who pre-register. https://lnkd.in/gjNUhpg3 Join us for this informative session and learn from one of the industry’s multi-disciplinary leaders!

📢 We are thrilled to share that Dr. Hyun Soo Park, CEO of molim Inc., has had his professorship extended at Seoul National University’s Graduate School of Convergence Science and Technology! Starting November 2024 and running through October 2027, Dr. Park will continue to serve as a visiting associate professor in the Department of Molecular Medicine and Biopharmaceuticals. 🎓 Dr. Park was first appointed in June 2016, and his role has been extended multiple times in recognition of his outstanding expertise and his dedication to nurturing future generations of researchers. With a rich background in nuclear medicine and his vision to empower researchers through advanced imaging technology, Dr. Park has truly made a lasting impact on his students and the field. Join us in congratulating Dr. Park on this well-deserved extension! 🌟

📢 Exciting Announcement! molim Inc. will be attending BIO-EUROPE 2024 in Stockholm, Sweden from November 4th to 6th! 🌍 We are thrilled to invite you to visit Booth 8, Level Ground, where you can meet Dr. Hyun Soo Park, our CEO and Founder, and Yujung Jang, our PM. They will be there to showcase molim’s cutting-edge advancements in nuclear medicine molecular imaging, which accelerates new drug development by up to 5x faster! 🧬 Dr. Hyunsoo Park, with a Ph.D. from Seoul National University in Nuclear Medicine, founded molim Inc. in 2022. His mission is to help bio-researchers succeed through advanced imaging technologies, offering immediate visualization and quantification for enhanced decision-making in drug development. With over 18 companies served, molim has quickly established itself as a trusted partner in the biotech industry. We look forward to meeting you at Bio Europe to discuss how molim can support your research and development efforts! 📅 Event Date: November 4-6, 2024 ⏰ Time: 09:00 - 19:00 📍 Booth: 8, Level Ground 🌐 Visit us at: www.molim.xyz #BIOEUROPE2024 #MolecularImaging #NuclearMedicine #BioTech #DrugDevelopment #molim #Innovation #CEOHyunsooPark

One of the biggest challenges when expanding overseas is definitely “language.” That’s why molim Inc. feels fortunate to have connected with VentureBlick in Singapore through K-Spor and the Korea Institute of Startup and Entrepreneurship Development for our first overseas expansion. We had the opportunity to meet with Chris Lee, CEO of VentureBlick, who is Korean but brings a wealth of global market experience. His insights offer tremendous value to startups aiming for global market expansion, no matter their nationality. On the 21st, we held a 1:1 meeting with Chris Lee for about an hour. It was a truly meaningful time, as his sharp corporate analysis helped molim identify and prioritize the key areas we need to strengthen for future market growth. We are deeply grateful to Chris Lee and VentureBlick for their continuous support. With their help, molim is committed to fulfilling our mission: to deliver cutting-edge science and technology to more researchers around the world, helping them succeed in their work. #molim #GlobalExpansion #VentureBlick #HealthcareInnovation #BioTech #StartupJourney #ChrisLee #MarketExpansion